A phase II trial of FLX 787 in patients with multiple sclerosis

Trial Profile

A phase II trial of FLX 787 in patients with multiple sclerosis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs FLX 787 (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Aug 2017 According to a Flex Pharma media release, the company expects important data readouts from this study in 2018.
    • 15 Jun 2016 Planned number of patients changed to 50, according to Flex Pharma media release.
    • 15 Jun 2016 Status changed from planning to recruiting, according to Flex Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top